PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer

Nanomedicine

Volumn 10, Issue 3, 2015, Pages 375-386

  Tse, Brian Wan Chi ^a   Cowin, Gary J ^b   Soekmadji, Carolina ^a   Jovanovic, Lidija ^a   Vasireddy, Raja S ^a   Ling, Ming Tat ^a   Khatri, Aparajita ^c   Liu, Tianqing ^d   Thierry, Benjamin ^d   Russell, Pamela J ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Ceramisphere Pty Ltd (Health Care Division)   (Australia)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

cancer imaging; iron oxide magnetic nanoparticles (MNPs); MRI; prostate cancer; prostate specific membrane antigen (PSMA); targeted imaging; targeted nanoparticles

Indexed keywords

CHLOROFORM; IRON OXIDE; IRON OXIDE MAGNETIC NANOPARTICLE; MAGNETIC NANOPARTICLE; MONOCLONAL ANTIBODY J591; OLEIC ACID; PHOSPHOLIPID; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; CONTRAST MEDIUM; FERRIC ION; FERRIC OXIDE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MAGNETITE NANOPARTICLE; MEMBRANE ANTIGEN;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CANCER CELL; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; IRON TRANSPORT; LNCAP CELL LINE; MALE; MICELLE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; STUDY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR XENOGRAFT; ANIMAL; DIAGNOSTIC USE; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; CONTRAST MEDIA; FERRIC COMPOUNDS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; MICE, INBRED NOD; MICE, SCID; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84923640108     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.122     Document Type: Article

References (35)

1. Yigit MV, Moore A, Medarova Z. Magnetic nanoparticles for cancer diagnosis and therapy. Pharm. Res. 29(5), 1180-1188 (2012
2. Taneja SS. Imaging in the diagnosis and management of prostate cancer. Rev. Urol. 6(3), 101-113 (2004
3. Liu G, Gao J, Ai H, Chen X. Applications and potential toxicity of magnetic iron oxide nanoparticles. Small 9(9-10), 1533-1545 (2013
4. Pouliquen D, Le Jeune JJ, Perdrisot R, Ermias A, Jallet P. Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism. Magn. Reson. Imaging 9(3), 275-283 (1991
5. To SY, Castro DJ, Lufkin RB, Soudant J, Saxton RE. Monoclonal antibody-coated magnetite particles as contrast agents for MR imaging and laser therapy of human tumors. J. Clin. Laser Med. Surg. 10(3), 159-169 (1992
6. Mahmoudi M, Serpooshan V, Laurent S. Engineered nanoparticles for biomolecular imaging. Nanoscale 3(8), 3007-3026 (2011
7. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 53(2), 227-230 (1993
8. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res. 58(21), 4787-4789 (1998
9. Schmittgen TD, Teske S, Vessella RL, True LD, Zakrajsek BA. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int. J. Cancer 107(2), 323-329 (2003
10. Wright GL Jr, Grob BM, Haley C., et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48(2), 326-334 (1996
11. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell. Biochem. 91(3), 528-539 (2004
12. Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol. Oncol. 1(1), 18-28 (1995
13. Liu H, Rajasekaran AK, Moy P., et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 58(18), 4055-4060 (1998
14. Rajasekaran SA, Anilkumar G, Oshima E., et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol. Biol. Cell 14(12), 4835-4845 (2003
15. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol. 23(21), 4591-4601 (2005
16. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90- labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol. 22(13), 2522-2531 (2004
17. Pinna N, Grancharov S, Beato P, Bonville P, Antonietti M, Niederberger M. Magnetite Nanocrystals: Nonaqueous Synthesis, Characterization, and Solubility. Chem. Mater. 17(11), 3044-3049 (2005
18. Thierry B, Al-Ejeh F, Brown M, Majewski P, Griesser H.J. Immunotargeting of Functional Nanoparticles for MRI detection of Apoptotic Tumor Cells. Adv. Mater. 21, 541-545 (2009
19. Thalmann GN, Anezinis PE, Chang SM., et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 54(10), 2577-2581 (1994
20. Wu TT, Sikes RA, Cui Q., et al. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int. J. Cancer 77(6), 887-894 (1998
21. Liu H, Moy P, Kim S., et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 57(17), 3629-3634 (1997
22. Chen H, Wang L, Yu Q., et al. Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer. Int. J. Nanomed. 8, 3781-3794 (2013
23. Schleich N, Sibret P, Danhier P., et al. Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. Int. J. Pharm. 447(1-2), 94-101 (2013
24. Bu L, Xie J, Chen K., et al. Assessment and comparison of magnetic nanoparticles as MRI contrast agents in a rodent model of human hepatocellular carcinoma. Contrast Media Mol. Imaging 7(4), 363-372 (2012
25. Morton DB. Humane endpoints in animal experiments for biomedical research: ethical, legal and practical aspects. Hendriksen CFM, Morton DB (Eds). Royal Society of Medicine Press. London, England p 5-12 (1999
26. Dubertret B, Skourides P, Norris DJ, Noireaux V, Brivanlou AH, Libchaber A. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science 298(5599), 1759-1762 (2002
27. Kelloff GJ, Choyke P, Coffey DS. Challenges in clinical prostate cancer: role of imaging. AJR Am. J. Roentgenol. 192(6), 1455-1470 (2009
28. Harisinghani M. Nanoparticle-enhanced MRI: are we there yet?. Lancet Oncol. 9(9), 814-815 (2008
29. Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Prostate-specific membrane antigen-based imaging. Urol. Oncol. 31(2), 144-154 (2013
30. Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann. Biomed. Eng. 34(1), 23-38 (2006
31. Colombo M, Carregal-Romero S, Casula MF., et al. Biological applications of magnetic nanoparticles. Chem. Soc. Rev. 41(11), 4306-4334 (2012
32. Bertrand N, Leroux JC. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J. Control. Release 161(2), 152-163 (2012
33. Abdolahi M, Shahbazi-Gahrouei D, Laurent S., et al. Synthesis and vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer. Contrast Media Mol. Imaging 8(2), 175-184 (2013
34. Tan M, Burden-Gulley SM, Li W., et al. MR molecular imaging of prostate cancer with a peptide-Targeted contrast agent in a mouse orthotopic prostate cancer model. Pharm. Res. 29(4), 953-960 (2012
35. Gao X, Luo Y, Wang Y., et al. Prostate stem cell antigen-Targeted nanoparticles with dual functional properties: vivo imaging and cancer chemotherapy. Int. J. Nanomed. 7, 4037-4051 (2012